Acadia Pharmaceuticals Inc. (0A4W)

Overview

ACADIA Pharmaceuticals Inc. is at the forefront of developing innovative medicines aimed at addressing the unmet medical needs within the realm of central nervous system (CNS) disorders and rare diseases in the United States. Transitioning from its former identity, Receptor Technologies, Inc., ACADIA has been operating under its current name since 1997, seamlessly continuing its mission of pioneering in the biopharmaceutical landscape. With its foundation laid in 1993 and a strategic headquarter in San Diego, California, ACADIA Pharmaceuticals Inc. is dedicated to leveraging cutting-edge science for the betterment of patients grappling with complex health conditions.

Products and Services

NUPLAZID (pimavanserin): This flagship product by ACADIA Pharmaceuticals is a groundbreaking treatment dedicated to addressing hallucinations and delusions associated with psychosis in Parkinson's disease patients. As the first of its kind, NUPLAZID represents a significant advancement in the therapeutic landscape for this challenging condition.

DAYBUE: As a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1, DAYBUE offers hope as a treatment option for patients suffering from Rett Syndrome. This innovation showcases ACADIA's commitment to extending its research and development efforts into the arena of rare diseases.

Pimavanserin: Currently under Phase III ADVANCE-2 study, Pimavanserin is being investigated for its efficacy in treating the negative symptoms of schizophrenia. This development signals ACADIA's dedication to expanding the potential therapeutic applications of its products.

ACP-101: With its focus on treating hyperphagia in individuals with Prader-Willi syndrome, ACP-101 is in Phase III, reflecting ACADIA's investment in addressing the challenges of rare genetic disorders.

ACP-204: Under Phase II study, ACP-204 is undergoing investigation for its potential to treat psychosis in Alzheimer's disease. This exploration into Alzheimer's disease psychosis underscores ACADIA's mission to combat neuropsychiatric symptoms associated with major neurocognitive disorders.

ACP-2591: Catering to Rett syndrome and Fragile X syndrome, ACP-2591 is in Phase I, exemplifying ACADIA's broader initiative in targeting genetic neurodevelopmental diseases.

Preclinical antisense oligonucleotide programs and other programs: These initiatives underscore ACADIA's commitment to innovation in neuropsychiatric symptom management across a variety of conditions, utilizing cutting-edge antisense oligonucleotide technology.

Through strategic collaborations, such as with Neuren Pharmaceuticals Limited for the development and commercialization of trofinetide for Rett syndrome and other indications, and with Stoke Therapeutics, Inc. for the creation of novel RNA-based medicines for severe and rare genetic neurodevelopmental diseases of the CNS, ACADIA is broadening its impact and reaching into new therapeutic areas.